Alto Neuroscience (NYSE:ANRO) Shares Down 8% After Earnings Miss

Alto Neuroscience, Inc. (NYSE:ANRO) traded down 8% on Wednesday following a dissappointing earnings announcement. The stock traded as low as $23.15 and last traded at $22.6620. 36,225 shares were traded during mid-day trading, a decline of 86% from the average session volume of 268,309 shares. The stock had previously closed at $24.63.

The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.24).

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Bank of America assumed coverage on Alto Neuroscience in a research note on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price target on the stock. Jefferies Financial Group restated a “buy” rating and set a $35.00 target price on shares of Alto Neuroscience in a research report on Monday, March 16th. JonesTrading decreased their price objective on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a research report on Thursday, April 2nd. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Alto Neuroscience in a report on Monday. Finally, Robert W. Baird lowered their target price on shares of Alto Neuroscience from $41.00 to $38.00 and set an “outperform” rating for the company in a report on Thursday, April 2nd. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $35.13.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC bought a new stake in Alto Neuroscience during the first quarter worth $52,000. Torren Management LLC bought a new stake in shares of Alto Neuroscience in the fourth quarter worth about $62,000. Invesco Ltd. purchased a new position in shares of Alto Neuroscience during the first quarter valued at about $67,000. Vanguard Personalized Indexing Management LLC raised its stake in Alto Neuroscience by 13.7% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock valued at $69,000 after buying an additional 2,055 shares during the last quarter. Finally, Bridgeway Capital Management LLC boosted its holdings in shares of Alto Neuroscience by 85.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after acquiring an additional 25,000 shares during the last quarter.

Alto Neuroscience Stock Down 7.6%

The company has a debt-to-equity ratio of 0.12, a current ratio of 15.69 and a quick ratio of 15.69. The company has a 50-day moving average of $23.09 and a two-hundred day moving average of $18.29. The company has a market capitalization of $727.12 million, a PE ratio of -10.39 and a beta of 1.62.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.